nitromethane-tris(3-propionate-O-2,3,5,6-tetrafluorophenyl ester) | 915944-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: nitromethane-tris(3-propionate-O-2,3,5,6-tetrafluorophenyl ester)
• CAS: 915944-73-9
• 化学式: C₂₈H₁₅F₁₂NO₈
• 分子量: 721.41
• InChiKey: XSZWSUZXPVBVFK-UHFFFAOYSA-N

物化性质

• 熔点：
  133.4-134.4 °C
• 沸点：
  697.5±55.0 °C(Predicted)
• 密度：
  1.590±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.83
• 重原子数：
  49.0
• 可旋转键数：
  13.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  122.04
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  nitromethane-tris(3-propionate-O-2,3,5,6-tetrafluorophenyl ester) 在 氢气 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， -78.0~20.0 ℃ 、310.27 kPa 条件下， 反应 16.0h， 生成 aminomethane-tris(N-(4,7,10-trioxa-13-tridecaneamino)-N-(tert-butyloxycarbonyl)-3-propionylamine)
  参考文献：
  名称：

  Design and Synthesis of Bis-Biotin-Containing Reagents for Applications Utilizing Monoclonal Antibody-Based Pretargeting Systems with Streptavidin Mutants

  摘要：

  Previous studies have shown that pretargeting protocols, using cancer-targeting fusion proteins, composed of 4 anti-CD20 single chain Fv (scFv) fragments and streptavidin (scFv(4)-SAv), followed by a biotinylated dendrimeric N-acetyl-galactosamine blood clearing agent (CA), 1, then a radiolabeled DOTA-biotin derivative (a monobiotin), 3a, can provide effective therapy for lymphoma xenografts in mouse models. A shortcoming in this pretargeting system is that endogenous biotin may affect its efficacy in patients. To circumvent this potential problem, we investigated a pretargeting system that employs anti-CD20 scFv(4)-SAv mutant fusion proteins with radioiodinated bis-biotin derivatives. With that combination of reagents, good localization of the radiolabel to lymphoma tumor xenografts was obtained in the presence of endogenous biotin. However, the blood clearance reagents employed in the studies were ineffective, resulting in abnormally high levels of radioactivity in other tissues. Thus, in the present investigation a bis-biotin-trigalactose blood clearance reagent, 2, was designed, synthesized, and evaluated in vivo. Additionally, another DOTA-biotin derivative (a bis-biotin), 4a, was designed and synthesized, such that radiometals (e.g., In-111, Y-90, Lu-177) could be used in the pretargeting protocols employing scFv(4)-SAv mutant fusion proteins. Studies in mice demonstrated that the CA 2 was more effective than CA 1 at removing [I-125]scFv(4)-SAv-S45A mutant fusion proteins from blood. Another in vivo study compared tumor targeting and normal tissue concentrations of the new reagents (2 and [In-111]4b) with standard reagents (1 and [In-111]3b) used in pretargeting protocols. The study showed that lymphoma xenografts could be targeted in the presence of endogenous biotin when anti-CD20 fusion potent containing SAv mutants (scFv(4)-SAv-S45A or scFv(4)-SAv-Y43A) were employed in combination with CA 2 and [In-111]4b). Importantly, normal tissue concentrations of [In-111]4b were similar to those obtained using the standard reagents (1 and [In-111]3b), except that the blood and liver concentrations were slightly higher with the new reagents. While the reasons for the higher blood and liver concentrations are unknown, the differences in the galactose structures of the clearance agents 1 and 2 may play a role.

  DOI：

  10.1021/bc100030q
• 作为产物：
  描述：

  硝基甲烷三丙酸 、 2,3,5,6-四氟苯基三氟乙酸盐 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以96%的产率得到nitromethane-tris(3-propionate-O-2,3,5,6-tetrafluorophenyl ester)
  参考文献：
  名称：

  Water soluble multi-biotin-containing compounds

  摘要：

  可溶于水的离散多生物素含有化合物，至少含有三个（3）生物素基团。这些可溶于水的生物素含有化合物可能还包括一个或多个使其对生物素酶的裂解具有抗性的基团，或者在体外或体内可被裂解的基团。这些离散的多生物素含有化合物可能包括一个反应性基团，提供与另一个基团（如靶向、诊断或治疗功能基团）反应的位点。还公开了包含可溶于水的连接基团的生物素化试剂，可能还包括生物素酶保护基团。还公开了使用多生物素化合物扩增在选定靶点上结合生物素结合蛋白的位点数量的方法。

  公开号：

  US20060228325A1